{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:25:28Z","timestamp":1788963928951,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T00:00:00Z","timestamp":1663977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine","award":["No: ZYYCXTD-D-202002"],"award-info":[{"award-number":["No: ZYYCXTD-D-202002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Poor in vivo targeting of tumors by chemotherapeutic drugs reduces their anti-cancer efficacy in the clinic. The discovery of over-expressed components on the tumor cell surface and their specific ligands provide a basis for targeting tumor cells. However, the differences in the expression levels of these receptors on the tumor cell surface limit the clinical application of anti-tumor preparations modified by a single ligand. Meanwhile, toxicity of chemotherapeutic drugs leads to poor tolerance to anti-tumor therapy. The discovery of natural active products antagonizing these toxic side effects offers an avenue for relieving cancer patients\u2019 pain during the treatment process. Since the advent of nanotechnology, interventions, such as loading appropriate drug combinations into nano-sized carriers and multiple tumor-targeting functional modifications on the carrier surface to enhance the anti-tumor effect and reduce toxic and side effects, have been widely used for treating tumors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Nanocarriers containing doxorubicin hydrochloride (DOX) and salvianolic acid A (Sal A) are spherical with a diameter of about 18\u00a0nm; the encapsulation efficiency of both DOX and salvianolic acid A is greater than 80%. E-[c(RGDfK)<jats:sub>2<\/jats:sub>]\/folic acid (FA) co-modification enabled nanostructured lipid carriers (NLC) to efficiently target a variety of tumor cells, including 4T1, MDA-MB-231, MCF-7, and A549 cells in vitro. Compared with other preparations (Sal A solution, NLC-Sal A, DOX solution, DOX injection, Sal A\/DOX solution, NLC-DOX, NLC-Sal A\/DOX, and E-[c(RGDfK)<jats:sub>2<\/jats:sub>]\/FA-NLC-Sal A\/DOX) in this experiment, the prepared E-[c(RGDfK)<jats:sub>2<\/jats:sub>]\/FA-NLC-Sal A\/DOX had the best anti-tumor effect. Compared with the normal saline group, it had the highest tumor volume inhibition rate (90.72%), the highest tumor weight inhibition rate (83.94%), led to the highest proportion of apoptosis among the tumor cells (61.30%) and the lowest fluorescence intensity of proliferation among the tumor cells (0.0083\u2009\u00b1\u20090.0011). Moreover, E-[c(RGDfK)<jats:sub>2<\/jats:sub>]\/FA-NLC-Sal A\/DOX had a low level of nephrotoxicity, with a low creatinine (Cre) concentration of 52.58\u00a0\u03bcmoL\/L in the blood of mice, and no abnormalities were seen on pathological examination of the isolated kidneys at the end of the study. Sal A can antagonize the nephrotoxic effect of DOX. Free Sal A reduced the Cre concentration of the free DOX group by 61.64%. In NLC groups, Sal A reduced the Cre concentration of the DOX group by 42.47%. The E-[c(RGDfK)<jats:sub>2<\/jats:sub>]\/FA modification reduced the side effects of the drug on the kidney, and the Cre concentration was reduced by 46.35% compared with the NLC-Sal A\/DOX group. These interventions can potentially improve the tolerance of cancer patients to chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The E-[c(RGDfK)<jats:sub>2<\/jats:sub>]\/FA co-modified DOX\/Sal A multifunctional nano-drug delivery system has a good therapeutic effect on tumors and low nephrotoxicity and is a promising anti-cancer strategy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12951-022-01628-x","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T15:15:59Z","timestamp":1664032559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["The anti-tumor and renoprotection study of E-[c(RGDfK)2]\/folic acid co-modified nanostructured lipid carrier loaded with doxorubicin hydrochloride\/salvianolic acid A"],"prefix":"10.1186","volume":"20","author":[{"given":"Bing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongli","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,24]]},"reference":[{"key":"1628_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.addbeh.2018.07.012","volume":"87","author":"CJ Berg","year":"2018","unstructured":"Berg CJ, Fong GT, Thrasher JF, Cohen JE, Maziak W, Lando H, et al. The impact and relevance of tobacco control research in low-and middle-income countries globally and to the US. Addict Behav. 2018;87:162\u20138.","journal-title":"Addict Behav"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1476-4598-10-80","volume":"10","author":"A Basseville","year":"2011","unstructured":"Basseville A, Preisser L, de Carn\u00e9 TS, Boisdron-Celle M, Gamelin E, Coqueret O, et al. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol Cancer. 2011;10:80.","journal-title":"Mol Cancer"},{"key":"1628_CR3","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1628_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","volume":"11","author":"PM Wilson","year":"2014","unstructured":"Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 2014;11(5):282\u201398.","journal-title":"Nat Rev Clin Oncol"},{"key":"1628_CR5","first-page":"9472782","volume":"2019","author":"Q Guo","year":"2019","unstructured":"Guo Q, Li X, Cui MN, Liang Y, Li XP, Zhao J, et al. Low-dose mitomycin C decreases the postoperative recurrence rate of pterygium by perturbing NLRP3 inflammatory signalling pathway and suppressing the expression of inflammatory factors. J Ophthalmol. 2019;2019:9472782.","journal-title":"J Ophthalmol"},{"issue":"28","key":"1628_CR6","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1200\/JCO.2017.72.4138","volume":"35","author":"ES Antonarakis","year":"2017","unstructured":"Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, et al. Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-na\u00efve, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2017;35(28):3181\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1628_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40169-018-0185-6","volume":"7","author":"H Maeda","year":"2018","unstructured":"Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med. 2018;7(1):11.","journal-title":"Clin Transl Med"},{"issue":"16","key":"1628_CR8","doi-asserted-by":"publisher","first-page":"9161","DOI":"10.1093\/nar\/gkaa660","volume":"48","author":"S Awate","year":"2020","unstructured":"Awate S, Sommers JA, Datta A, Nayak S, Bellani MA, Yang O, et al. FANCJ compensates for RAP80 deficiency and suppresses genomic instability induced by interstrand cross-links. Nucleic Acids Res. 2020;48(16):9161\u201380.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1628_CR9","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1200\/JCO.18.00889","volume":"37","author":"C Craddock","year":"2019","unstructured":"Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, et al. Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia. J Clin Oncol. 2019;37(7):580\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1628_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1021\/acscentsci.8b00688","volume":"5","author":"X Liu","year":"2019","unstructured":"Liu X, Wang B, Li Y, Hu Y, Li X, Yu T, et al. Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system. ACS Cent Sci. 2019;5(2):277\u201389.","journal-title":"ACS Cent Sci"},{"key":"1628_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1476-4598-9-84","volume":"9","author":"MS Aguzzi","year":"2010","unstructured":"Aguzzi MS, Fortugno P, Giampietri C, Ragone G, Capogrossi MC, Facchiano A. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010;9:84.","journal-title":"Mol Cancer"},{"issue":"1","key":"1628_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/nar\/gkz1115","volume":"48","author":"L Salim","year":"2020","unstructured":"Salim L, Islam G, Desaulniers JP. Targeted delivery and enhanced gene-silencing activity of centrally modified folic acid-siRNA conjugates. Nucleic Acids Res. 2020;48(1):75\u201385.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1628_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12943-018-0937-3","volume":"18","author":"G S\u00f6keland","year":"2019","unstructured":"S\u00f6keland G, Schumacher U. The functional role of integrins during intra- and extravasation within the metastatic cascade. Mol Cancer. 2019;18(1):12.","journal-title":"Mol Cancer"},{"issue":"1\u20132","key":"1628_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.03.017","volume":"543","author":"B Li","year":"2018","unstructured":"Li B, Zhang XX, Huang HY, Chen LQ, Cui JH, Liu Y, et al. Effective deactivation of A549 tumor cells in vitro and in vivo by RGD-decorated chitosan-functionalized single-walled carbon nanotube loading docetaxel. Int J Pharm. 2018;543(1\u20132):8\u201320.","journal-title":"Int J Pharm"},{"key":"1628_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.biopha.2015.12.007","volume":"77","author":"\u00d6 Berrak","year":"2016","unstructured":"Berrak \u00d6, Akko\u00e7 Y, Ar\u0131san ED, \u00c7oker-G\u00fcrkan A, Obakan-Yerlikaya P, Palavan-\u00dcnsal N. The inhibition of PI3K and NF\u03baB promoted curcumin-induced cell cycle arrest at G2\/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. Biomed Pharmacother. 2016;77:150\u201360.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"1628_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341\u201354.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1628_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","volume":"7","author":"S Li","year":"2005","unstructured":"Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301\u201311.","journal-title":"Cancer Cell"},{"issue":"2","key":"1628_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jconrel.2004.08.017","volume":"100","author":"HS Yoo","year":"2004","unstructured":"Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release. 2004;100(2):247\u201356.","journal-title":"J Control Release"},{"issue":"1","key":"1628_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41467-021-21618-1","volume":"12","author":"B Zhao","year":"2021","unstructured":"Zhao B, Wang Y, Yao X, Chen D, Fan M, Jin Z, et al. Photocatalysis-mediated drug-free sustainable cancer therapy using nanocatalyst. Nat Commun. 2021;12(1):1345.","journal-title":"Nat Commun"},{"issue":"4","key":"1628_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2174\/156720108785915087","volume":"5","author":"SS Shidhaye","year":"2008","unstructured":"Shidhaye SS, Vaidya R, Sutar S, Patwardhan A, Kadam VJ. Solid lipid nanoparticles and nanostructured lipid carriers\u2014innovative generations of solid lipid carriers. Curr Drug Deliv. 2008;5(4):324\u201331.","journal-title":"Curr Drug Deliv"},{"issue":"1","key":"1628_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejpb.2013.08.013","volume":"86","author":"S Weber","year":"2014","unstructured":"Weber S, Zimmer A, Pardeike J. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur J Pharm Biopharm. 2014;86(1):7\u201322.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1628_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijpharm.2006.01.022","volume":"314","author":"A Saupe","year":"2006","unstructured":"Saupe A, Gordon KC, Rades T. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int J Pharm. 2006;314(1):56\u201362.","journal-title":"Int J Pharm"},{"issue":"22","key":"1628_CR23","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.2174\/0929867326666190624155938","volume":"27","author":"B Fonseca-Santos","year":"2020","unstructured":"Fonseca-Santos B, Silva PB, Rigon RB, Sato MR, Chorilli M. Formulating SLN and NLC as innovative drug delivery systems for non-invasive routes of drug administration. Curr Med Chem. 2020;27(22):3623\u201356.","journal-title":"Curr Med Chem"},{"issue":"12","key":"1628_CR24","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751\u201360.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"1628_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"A Kumari","year":"2010","unstructured":"Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75(1):1\u201318.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1628_CR26","doi-asserted-by":"publisher","first-page":"29653","DOI":"10.1038\/srep29653","volume":"6","author":"DH Kim","year":"2016","unstructured":"Kim DH, Li W, Chen J, Zhang Z, Green RM, Huang S, et al. Multimodal imaging of nanocomposite microspheres for transcatheter intra-arterial drug delivery to liver tumors. Sci Rep. 2016;6:29653.","journal-title":"Sci Rep"},{"issue":"1","key":"1628_CR27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1080\/10717544.2018.1450910","volume":"25","author":"G Huang","year":"2018","unstructured":"Huang G, Huang H. Application of hyaluronic acid as carriers in drug delivery. Drug Deliv. 2018;25(1):766\u201372.","journal-title":"Drug Deliv"},{"issue":"13","key":"1628_CR28","doi-asserted-by":"publisher","first-page":"e2106350","DOI":"10.1002\/adma.202106350","volume":"34","author":"SB Yong","year":"2022","unstructured":"Yong SB, Ramishetti S, Goldsmith M, Diesendruck Y, Hazan-Halevy I, Chatterjee S, et al. Dual-targeted lipid nanotherapeutic boost for chemo-immunotherapy of cancer. Adv Mater. 2022;34(13):e2106350.","journal-title":"Adv Mater"},{"key":"1628_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fphar.2020.00898","volume":"11","author":"H Yan","year":"2020","unstructured":"Yan H, You Y, Li X, Liu L, Guo F, Zhang Q, et al. Preparation of RGD peptide\/folate acid double-targeted mesoporous silica nanoparticles and its application in human breast cancer MCF-7 cells. Front Pharmacol. 2020;11:898.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1628_CR30","doi-asserted-by":"publisher","first-page":"5717","DOI":"10.1021\/nn2013904","volume":"5","author":"T Yu","year":"2011","unstructured":"Yu T, Malugin A, Ghandehari H. Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. ACS Nano. 2011;5(7):5717\u201328.","journal-title":"ACS Nano"},{"issue":"25","key":"1628_CR31","doi-asserted-by":"publisher","first-page":"13637","DOI":"10.1039\/D0NR03208E","volume":"12","author":"X Chen","year":"2020","unstructured":"Chen X, Zhu S, Hu X, Sun D, Yang J, Yang C, et al. Toxicity and mechanism of mesoporous silica nanoparticles in eyes. Nanoscale. 2020;12(25):13637\u201353.","journal-title":"Nanoscale"},{"key":"1628_CR32","doi-asserted-by":"publisher","first-page":"124502","DOI":"10.1016\/j.jhazmat.2020.124502","volume":"409","author":"YD Deng","year":"2021","unstructured":"Deng YD, Zhang XD, Yang XS, Huang ZL, Wei X, Yang XF, et al. Subacute toxicity of mesoporous silica nanoparticles to the intestinal tract and the underlying mechanism. J Hazard Mater. 2021;409:124502.","journal-title":"J Hazard Mater"},{"issue":"2","key":"1628_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijpharm.2015.09.033","volume":"495","author":"F Brug\u00e8","year":"2015","unstructured":"Brug\u00e8 F, Damiani E, Marcheggiani F, Offerta A, Puglia C, Tiano L. A comparative study on the possible cytotoxic effects of different nanostructured lipid carrier (NLC) compositions in human dermal fibroblasts. Int J Pharm. 2015;495(2):879\u201385.","journal-title":"Int J Pharm"},{"issue":"6","key":"1628_CR34","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.tiv.2014.12.021","volume":"29","author":"LP Mendes","year":"2015","unstructured":"Mendes LP, Delgado JM, Costa AD, Vieira MS, Benfica PL, Lima EM, et al. Biodegradable nanoparticles designed for drug delivery: the number of nanoparticles impacts on cytotoxicity. Toxicol In Vitro. 2015;29(6):1268\u201374.","journal-title":"Toxicol In Vitro"},{"issue":"2","key":"1628_CR35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00259-006-0180-9","volume":"34","author":"I Dijkgraaf","year":"2007","unstructured":"Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, Oyen WJ, Corstens FH, et al. Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. Eur J Nucl Med Mol Imaging. 2007;34(2):267\u201373.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1628_CR36","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.2147\/IJN.S202424","volume":"14","author":"D Kebebe","year":"2019","unstructured":"Kebebe D, Wu Y, Zhang B, Yang J, Liu Y, Li X, et al. Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer. Int J Nanomed. 2019;14:6179\u201395.","journal-title":"Int J Nanomed"},{"issue":"5","key":"1628_CR37","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","volume":"64","author":"AZ Wilczewska","year":"2012","unstructured":"Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacol Rep. 2012;64(5):1020\u201337.","journal-title":"Pharmacol Rep"},{"key":"1628_CR38","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fphar.2018.01358","volume":"9","author":"G Maniam","year":"2018","unstructured":"Maniam G, Mai CW, Zulkefeli M, Duf\u00e8s C, Tan DM, Fu JY. Challenges and opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Front Pharmacol. 2018;9:1358.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1628_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.drudis.2019.09.023","volume":"25","author":"Q Liu","year":"2020","unstructured":"Liu Q, Guan J, Qin L, Zhang X, Mao S. Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery. Drug Discov Today. 2020;25(1):150\u20139.","journal-title":"Drug Discov Today"},{"key":"1628_CR40","first-page":"3","volume":"8","author":"X Su","year":"2021","unstructured":"Su X, Zhang X, Liu W, Yang X, An N, Yang F, et al. Advances in the application of nanotechnology in reducing cardiotoxicity induced by cancer chemotherapy. Semin Cancer Biol. 2021;8:3.","journal-title":"Semin Cancer Biol"},{"issue":"Suppl 1","key":"1628_CR41","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/S0145-2126(98)00036-8","volume":"22","author":"JJ Griggs","year":"1998","unstructured":"Griggs JJ. Reducing the toxicity of anticancer therapy: new strategies. Leuk Res. 1998;22(Suppl 1):S27-33.","journal-title":"Leuk Res"},{"issue":"25","key":"1628_CR42","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","volume":"16","author":"C Carvalho","year":"2009","unstructured":"Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267\u201385.","journal-title":"Curr Med Chem"},{"key":"1628_CR43","doi-asserted-by":"publisher","first-page":"12273","DOI":"10.1038\/srep12273","volume":"5","author":"HY Fan","year":"2015","unstructured":"Fan HY, Yang MY, Qi D, Zhang ZK, Zhu L, Shang-Guan XX, et al. Salvianolic acid A as a multifunctional agent ameliorates doxorubicin-induced nephropathy in rats. Sci Rep. 2015;5:12273.","journal-title":"Sci Rep"},{"issue":"7","key":"1628_CR44","first-page":"496","volume":"39","author":"SH Zhang","year":"2004","unstructured":"Zhang SH, Su J, Zhen YS. Salvianolic acid A inhibits nucleoside transport and potentiates the antitumor activity of chemotherapeutic drugs. Yao Xue Xue Bao. 2004;39(7):496\u20139.","journal-title":"Yao Xue Xue Bao"},{"key":"1628_CR45","doi-asserted-by":"publisher","first-page":"105599","DOI":"10.1016\/j.bioorg.2022.105599","volume":"120","author":"S Alam Khan","year":"2022","unstructured":"Alam Khan S, Jawaid AM. Structural modification and strategies for the enhanced doxorubicin drug delivery. Bioorg Chem. 2022;120:105599.","journal-title":"Bioorg Chem"},{"issue":"5","key":"1628_CR46","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0731-7085(03)00655-1","volume":"34","author":"OT Fahmy","year":"2004","unstructured":"Fahmy OT, Korany MA, Maher HM. High performance liquid chromatographic determination of some co-administered anticancer drugs in pharmaceutical preparations and in spiked human plasma. J Pharm Biomed Anal. 2004;34(5):1099\u2013107.","journal-title":"J Pharm Biomed Anal"},{"key":"1628_CR47","first-page":"807","volume":"6","author":"C Wu","year":"2011","unstructured":"Wu C, Yu C, Chu M. A gold nanoshell with a silica inner shell synthesized using liposome templates for doxorubicin loading and near-infrared photothermal therapy. Int J Nanomed. 2011;6:807\u201313.","journal-title":"Int J Nanomed"},{"issue":"6","key":"1628_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/bmc.791","volume":"21","author":"YY Hou","year":"2007","unstructured":"Hou YY, Peng JM, Chao RB. Pharmacokinetic study of salvianolic acid A in rat after intravenous administration of Danshen injection. Biomed Chromatogr. 2007;21(6):598\u2013601.","journal-title":"Biomed Chromatogr"},{"key":"1628_CR49","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejpb.2017.04.013","volume":"117","author":"JS Baek","year":"2017","unstructured":"Baek JS, Cho CW. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132\u201340.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"1628_CR50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/pharmaceutics13050600","volume":"13","author":"Z Ma","year":"2021","unstructured":"Ma Z, Pi J, Zhang Y, Qin H, Zhang B, Li N, et al. Enhanced anticancer efficacy of dual drug-loaded self-assembled nanostructured lipid carriers mediated by pH-responsive folic acid and human-derived cell penetrating peptide dNP2. Pharmaceutics. 2021;13(5):600.","journal-title":"Pharmaceutics"},{"key":"1628_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.msec.2017.03.145","volume":"76","author":"L Jaimes-Aguirre","year":"2017","unstructured":"Jaimes-Aguirre L, Morales-Avila E, Ocampo-Garc\u00eda BE, Medina LA, L\u00f3pez-T\u00e9llez G, Gibbens-Bandala BV, et al. Biodegradable poly(D, L-lactide-co-glycolide)\/poly(L-\u03b3-glutamic acid) nanoparticles conjugated to folic acid for targeted delivery of doxorubicin. Mater Sci Eng C Mater Biol Appl. 2017;76:743\u201351.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"12","key":"1628_CR52","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00004424-199712000-00005","volume":"32","author":"EC Wiener","year":"1997","unstructured":"Wiener EC, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest Radiol. 1997;32(12):748\u201354.","journal-title":"Invest Radiol"},{"issue":"9","key":"1628_CR53","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/jcmm.13110","volume":"21","author":"S Salatin","year":"2017","unstructured":"Salatin S, Yari KA. Overviews on the cellular uptake mechanism of polysaccharide colloidal nanoparticles. J Cell Mol Med. 2017;21(9):1668\u201386.","journal-title":"J Cell Mol Med"},{"issue":"40","key":"1628_CR54","doi-asserted-by":"publisher","first-page":"e1902409","DOI":"10.1002\/adma.201902409","volume":"31","author":"J He","year":"2019","unstructured":"He J, Li C, Ding L, Huang Y, Yin X, Zhang J, et al. Tumor targeting strategies of smart fluorescent nanoparticles and their applications in cancer diagnosis and treatment. Adv Mater. 2019;31(40):e1902409.","journal-title":"Adv Mater"},{"issue":"10","key":"1628_CR55","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/s41419-018-1046-3","volume":"9","author":"Z Feng","year":"2018","unstructured":"Feng Z, Xia Y, Gao T, Xu F, Lei Q, Peng C, et al. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0\/G1 arrest and apoptosis. Cell Death Dis. 2018;9(10):1006.","journal-title":"Cell Death Dis"},{"issue":"16","key":"1628_CR56","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1093\/hmg\/ddw262","volume":"25","author":"N Miller","year":"2016","unstructured":"Miller N, Shi H, Zelikovich AS, Ma YC. Motor neuron mitochondrial dysfunction in spinal muscular atrophy. Hum Mol Genet. 2016;25(16):3395\u2013406.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"1628_CR57","doi-asserted-by":"publisher","first-page":"712","DOI":"10.18632\/aging.100926","volume":"8","author":"A Pann\u00e9rec","year":"2016","unstructured":"Pann\u00e9rec A, Springer M, Migliavacca E, Ireland A, Piasecki M, Karaz S, et al. A robust neuromuscular system protects rat and human skeletal muscle from sarcopenia. Aging (Albany NY). 2016;8(4):712\u201329.","journal-title":"Aging (Albany NY)"},{"key":"1628_CR58","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/IJN.S159789","volume":"13","author":"X Yuan","year":"2018","unstructured":"Yuan X, Fei F, Sun H, Xiao C, Zhao X, Zhang Y, et al. Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo. Int J Nanomed. 2018;13:2265\u201374.","journal-title":"Int J Nanomed"},{"issue":"2","key":"1628_CR59","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1021\/nn405155b","volume":"8","author":"RI El-Gogary","year":"2014","unstructured":"El-Gogary RI, Rubio N, Wang JT, Al-Jamal WT, Bourgognon M, Kafa H, et al. Polyethylene glycol conjugated polymeric nanocapsules for targeted delivery of quercetin to folate-expressing cancer cells in vitro and in vivo. ACS Nano. 2014;8(2):1384\u2013401.","journal-title":"ACS Nano"},{"key":"1628_CR60","doi-asserted-by":"publisher","first-page":"44758","DOI":"10.1038\/srep44758","volume":"7","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Tang S, Guo J, Alahdal M, Cao S, Yang Z, et al. Targeted delivery of doxorubicin by nano-loaded mesenchymal stem cells for lung melanoma metastases therapy. Sci Rep. 2017;7:44758.","journal-title":"Sci Rep"},{"issue":"10","key":"1628_CR61","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/clinchem\/38.10.1933","volume":"38","author":"RD Perrone","year":"1992","unstructured":"Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38(10):1933\u201353.","journal-title":"Clin Chem"},{"key":"1628_CR62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.lfs.2018.03.023","volume":"200","author":"A Pugazhendhi","year":"2018","unstructured":"Pugazhendhi A, Edison T, Velmurugan BK, Jacob JA, Karuppusamy I. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018;200:26\u201330.","journal-title":"Life Sci"},{"issue":"2","key":"1628_CR63","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1001\/archinte.1991.00400020036008","volume":"151","author":"KE Sherman","year":"1991","unstructured":"Sherman KE. Alanine aminotransferase in clinical practice. A review. Arch Intern Med. 1991;151(2):260\u20135.","journal-title":"Arch Intern Med"},{"key":"1628_CR64","doi-asserted-by":"publisher","first-page":"104276","DOI":"10.1016\/j.phrs.2019.104276","volume":"146","author":"X Zhao","year":"2019","unstructured":"Zhao X, Jin Y, Li L, Xu L, Tang Z, Qi Y, et al. MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1. Pharmacol Res. 2019;146:104276.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1628_CR65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1172\/JCI109467","volume":"64","author":"SE Steinberg","year":"1979","unstructured":"Steinberg SE, Campbell CL, Hillman RS. Kinetics of the normal folate enterohepatic cycle. J Clin Invest. 1979;64(1):83\u20138.","journal-title":"J Clin Invest"},{"issue":"11","key":"1628_CR66","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/nmat4718","volume":"15","author":"KM Tsoi","year":"2016","unstructured":"Tsoi KM, MacParland SA, Ma XZ, Spetzler VN, Echeverri J, Ouyang B, et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater. 2016;15(11):1212\u201321.","journal-title":"Nat Mater"},{"issue":"1","key":"1628_CR67","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41598-017-07162-3","volume":"7","author":"C Chen","year":"2017","unstructured":"Chen C, Nong Z, Xie Q, He J, Cai W, Tang X, et al. 2-Dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione inhibits the growth and metastasis of breast carcinoma in mice. Sci Rep. 2017;7(1):6704.","journal-title":"Sci Rep"},{"issue":"7\u20138","key":"1628_CR68","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.intimp.2009.03.015","volume":"9","author":"HK Le","year":"2009","unstructured":"Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol. 2009;9(7\u20138):900\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"1628_CR69","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.7150\/ijms.41980","volume":"17","author":"Z Li","year":"2020","unstructured":"Li Z, Li H, Liu B, Luo J, Qin X, Gong M, et al. Inhibition of miR-25 attenuates doxorubicin-induced apoptosis, reactive oxygen species production and DNA damage by targeting PTEN. Int J Med Sci. 2020;17(10):1415\u201327.","journal-title":"Int J Med Sci"},{"key":"1628_CR70","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2147\/IJN.S187153","volume":"14","author":"R Stephens","year":"2019","unstructured":"Stephens R, Tredwell G, Knox K, Philip L, King D, Debono K, et al. 99mTc-radiolabeled composites enabling in vivo imaging of arterial dispersal and retention of microspheres in the vascular network of rabbit lungs, liver, and liver tumors. Int J Nanomed. 2019;14:889\u2013900.","journal-title":"Int J Nanomed"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01628-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T11:08:34Z","timestamp":1664104114000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,24]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01628-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,24]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were operated under the approval of the Ethics Committee of Tianjin University of Traditional Chinese Medicine (Ethics authorization number: TCM-LAEC2019026).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"425"}}